Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients

Dermatologic Surgery

Volumn 39, Issue 4, 2013, Pages 634-645

  Endrizzi, Bart ^a   Ahmed, Rehana L ^a   Ray, Theresa ^a   Dudek, Arkadiusz ^a   Lee, Peter ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CAPECITABINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACTINIC KERATOSIS; ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL OBSERVATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; GOUT; GRAFT RECIPIENT; HAND FOOT SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NONMELANOMA SKIN CARCINOMA; PRIORITY JOURNAL; SCREENING TEST; SIDE EFFECT; SKIN CARCINOMA; SOLID ORGAN TRANSPLANT RECIPIENT; SQUAMOUS CELL CARCINOMA; TOXICITY TESTING; TREATMENT DURATION; TUMOR LYSIS SYNDROME; TUMOR VOLUME; WEAKNESS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, BASAL CELL; CHILD; CHILD, PRESCHOOL; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEOPLASMS, SQUAMOUS CELL; ORGAN TRANSPLANTATION; SKIN NEOPLASMS; TUMOR BURDEN; YOUNG ADULT;

EID: 84875803484     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/dsu.12049     Document Type: Article

References (33)

1. Cleemput I, Dobbels F,. Measuring patient-reported outcomes in solid organ transplant recipients: an overview of instruments developed to date. Pharmacoeconomics 2007; 25 (4): 269-86.
2. Kuijken I, Bouwes Bavinck JN,. Skin cancer risk associated with immunosuppressive therapy in organ transplant recipients: epidemiology and proposed mechanisms. BioDrugs, 2000; 14 (5): 319-29.
3. Quatresooz P, Pierard-Franchimont C,. Cutaneous cancers after organ transplantation. Rev Med Liege 2007; 62 (11): 663-8.
4. Schilsky RL, Bertucci D, Vogelzang NJ, Kindler HL, Ratain MJ,. Dose escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 2002; 20 (2): 582-7.
5. Euvrard S, Kanitakis J, Claudy A,. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-91.
6. Herman S, Ratner D,. Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant recipients. Skinmed 2007; 6 (5): 234-8.
7. Berg D, Otley CC,. Skin Cancer in organ transplant recipients. Epidemiology, pathogenesis and management. J Am Acad Dermatol 2002; 47: 1-17.
8. Euvrard S, Kanitakis J, Claudy A,. Skin cancers after solid organ transplantation. N Engl J Med 2003; 348: 1681-91.
9. Tessari G, Girolomoni G,. Incidence and clinical predictors of subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer. Arch Dermatol, 2010; 146 (3): 294-9.
10. Hofbauer GFL, Bouwes Bavink JN, Euvrard S,. Organ transplantation and skin cancer: basic problems and new perspectives. Exp Dermatol 2010; 19: 473-82.
11. Miwa M, Ura M, Nishida M, Sawada N, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-81.
12. Mori K, Hasegawa M, Nishida M, Toma H, et al. Expression levels of thymidine phosphorylase and dihydro-pyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 2000; 17: 33-8.
13. Dooley M, Goa KL,. Capecitabine. Drugs 1999; 58 (1): 69-76.
14. Higa GM, Kovach RF, Abraham J,. Actinic keratosis and Capecitabine therapy. J Oncol Pharm Practice 2005; 11: 151-3.
15. Lewis G, Lewis DM, Robinson-Bostom L, Pan TD,. Inflammation of actinic keratoses during Capecitabine therapy. Arch Dermatol 2004; 140: 367-8.
16. Peramiquel L, Alomar A,. Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment. J Am Acad Dermatol 2006; 55 (5 Suppl): S119-20.
17. Khansur T, Allred C, Little D, Anand V,. Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. Cancer Invest 1995; 13: 263-6.
18. Cartei G, Cartei F, Interlandi G, Meneghini G, et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 2000; 23: 181-4.
19. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, et al. Positive correlation between the effect of capecitabine and deoxyfluorodine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumor in human cancer xenografts. Cancer Res 1998; 58: 685-90.
20. Sadek H, Azli N, Wendling JL, Cvitkovic E, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 1990; 66: 1692-6.
21. Kang Y, Kang K, Shin B, Xiong J,. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. PASCO. 2006; LBA; 4018
22. Wollina U, Kostler E,. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol 2005; 131 (5): 300-4.
23. Son J, Marshal J,. Safety of chronic low-dose capecitabine as maintanence therapy in gastrointestinal cancers. Gastrointest Cancer Res 2009; 3 (4): 134-40.
24. Endrizzi B, Lee P,. Management of carcinoma of the skin in solid organ transplant recipients with oral capecitabine. Dermatol Surg, 2009; 35 (10): 1567-72.
25. Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, Teqzess AM,. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant 2011; 25 (4): 541-8.
26. Oken MM, Creech RH, Tormey DC, Horton J, Cutmore S,. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.-ECOG ref
27. Mosteller RD,. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.
28. Lee SS, Lee J-L, Ruy M-H, Chang HM, et al. Combination chemotherapy with Capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol 2007; 37 (1): 30-7.
29. Bouwes Bavink JN, Hardie DR, Green A, Cutmore S,. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996; 61: 715-21.
30. Bouwes Bavink JN, Tieben LM, Van der Woude FJ, Teqzess AM,. Prevention of skin cancer and reduction of keratotic lesions during acitretin therapy in renal transplant recipients: a double-blinded placebo controlled study. J Clin Oncol 1995; 13: 1933-8.
31. Chen K, Craig JC, Shumack S,. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005; 152: 518-23.
32. George R, Weightman W, Russ GR, Bannister KM, Mathew TH,. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43: 269-73.
33. De Sevaux RGL, Smit JV, de Jong EM, Van de Kerkhot PC, et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomised trial comparing two doses of acitretin. J Am Acad Dermatol 2003; 49: 407-12.